Chronic obstructive pulmonary disease (COPD) remains a leading cause of death
worldwide, yet only one new drug class has been approved in the last decade. However …

Clinical phenotyping is currently used to guide pharmacological treatment decisions in
chronic obstructive pulmonary disease (COPD), a personalized approach to care. Precision …

Highlights•Several phenotypes characterize chronic obstructive pulmonary disease
(COPD).•Response to pharmacological treatment in COPD is highly variable.•Guidelines …

Background: In 2008, a dedicated American Thoracic Society/European Respiratory Society
task force published a paper on the possible use and limitations of clinical outcomes and …

Introduction: Treatment recommendations are based on randomized controlled trials (RCTs).
However, only about 1 in 20 people meet the inclusion criteria for RCTs forming consensus …

Chronic obstructive pulmonary disease (COPD) is a leading cause of disability and mortality.
Caring for patients with COPD, particularly those with advanced disease who experience …

Although chronic obstructive pulmonary disease (COPD) is a major global health problem
with a rising incidence and morbidity, few pharmacotherapeutic advances have been made …

Bronchodilators, corticosteroids, and antibiotics are still key elements for treating chronic
obstructive pulmonary disease in the 2019 Global Initiative for Chronic Obstructive Lung …

Chronic obstructive pulmonary disease (COPD) is the fourth leading cause of death across
the globe. Its repeated exacerbation will seriously worsen the quality of life, aggravate the …

The American Thoracic Society/European Respiratory Society jointly created a Task Force
on “Outcomes for COPD pharmacological trials: from lung function to biomarkers” to inform …